Effective Date:

Monday, May 04, 2015

Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, May 04, 2015

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

NMS LABS
3701 Welsh Road
Willow Grove, PA 19090
www.NMSLabs.com

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
0165SP	Albuterol, Serum/Plasma			•	•				
0796SP	Bumetanide, Serum/Plasma				•				
1180SP	Chlorothiazide, Serum/Plasma				•				
1250SP	Chlorthalidone, Serum/Plasma				•				
1515SP	Diazoxide, Serum/Plasma				•				
1760SP	Diphenhydramine, Serum/Plasma				•				
1760U	Diphenhydramine, Urine				•				
1804SP	Diuretics Panel, Serum/Plasma				•				
8898OF	Drugs of Abuse (6 Panel) (Qualitative), Oral Fluid (Saliva)							•	
8897OF	Drugs of Abuse (7 Panel) (Qualitative), Oral Fluid (Saliva)							•	
1900SP	Dyazide, Serum/Plasma				•				
2069B	Felbamate, Blood			•	•			•	
2069SP	Felbamate, Serum/Plasma			•	•			•	
2100B	Fluorocarbons (22, 113) Panel, Blood	•		•		•			
2100TI	Fluorocarbons (22, 113) Panel, Tissue	•				•			
52155SP	Furosemide Confirmation, Serum/Plasma (Forensic) (CSA)				•				
9545SP	Furosemide Screen (Add-On), Serum/Plasma (Forensic) (CSA)				•				
2140SP	Furosemide, Serum/Plasma				•				
52156SP	Hydrochlorothiazide Confirmation, Serum/Plasma (Forensic) (CSA)				•				
9546SP	Hydrochlorothiazide Screen (Add-On), Serum/Plasma (Forensic) (CSA)				•				
2330SP	Hydrochlorothiazide, Serum/Plasma				•				
2345SP	Hydroflumethiazide, Serum/Plasma				•				
2365U	Hydroxyzine and Metabolite, Urine				•				
2397SP	Indapamide, Serum/Plasma				•				
2414B	Inhalants Panel, Halocarbons, Blood					•			
2414TI	Inhalants Panel, Halocarbons, Tissue					•			
54355B	Lacosamide Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic)			•	•			•	
54355SP	Lacosamide Confirmation (Drug Impaired Driving/DRE Toxicology), Serum/Plasma (Forensic)			•	•			•	
54355U	Lacosamide Confirmation (Drug Impaired Driving/DRE Toxicology), Urine (Forensic)			•				•	

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
52420B	Lacosamide Confirmation, Blood (Forensic)				•			•	
52420SP	Lacosamide Confirmation, Serum/Plasma (Forensic)			•	•			•	
52420U	Lacosamide Confirmation, Urine (Forensic)			•				•	
2527B	Lacosamide, Blood			•	•			•	
2527SP	Lacosamide, Serum/Plasma				•			•	
10020SP	Lacosamide, Serum/Plasma (CSA)				•			•	
2527U	Lacosamide, Urine			•				•	
3042SP	Metolazone, Serum/Plasma				•				
8895OF	Opiates (Qualitative), Oral Fluid (Saliva)							•	
5852OF	Opiates Confirmation (Qualitative), Oral Fluid (Saliva) (Forensic)							•	
3372B	PCBs, PBBs and Organochlorine Pesticides, Blood								•
8889OF	ProofPOSITIVE® Drug Impaired Driving/DRE Toxicology Panel (Qualitative), Oral Fluid (Saliva) (CSA)							•	
4125B	Rufinamide, Blood				•		•	•	
4125SP	Rufinamide, Serum/Plasma				•		•	•	
4525SP	Torsemide, Serum/Plasma				•				
4540SP	Triamterene, Serum/Plasma				•				
4844N	Zinc, Nails		•					•	

Test Updates

Test Changes

0165SP Albuterol, Serum/Plasma

Summary of Changes:	Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed.
Specimen Requirements:	3 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 12 month(s)

0796SP Bumetanide, Serum/Plasma

Summary of Changes:	Stability was changed.
Stability:	Room Temperature: 1 month(s) Refrigerated: 1 month(s) Frozen (-20 °C): 24 month(s)

1180SP Chlorothiazide, Serum/Plasma

Summary of Changes:	Stability was changed.
Stability:	Room Temperature: 14 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 24 month(s)

1250SP Chlorthalidone, Serum/Plasma

Summary of Changes:	Stability was changed.
Stability:	Room Temperature: 1 month(s) Refrigerated: 1 month(s) Frozen (-20 °C): 24 month(s)

1515SP Diazoxide, Serum/Plasma

Summary of Changes:	Stability was changed.
Stability:	Room Temperature: 14 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 24 month(s)

Test Updates

Test Changes

1760SP Diphenhydramine, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 1 month(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 24 month(s)

1760U Diphenhydramine, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 1 month(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 24 month(s)

1804SP Diuretics Panel, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 24 month(s)

8898OF Drugs of Abuse (6 Panel) (Qualitative), Oral Fluid (Saliva)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80324, 80346, 80353, 80356, 80358, 80359, 80362, 80365): Amphetamine, Methamphetamine, MDA, MDMA, Diazepam, Nordiazepam, Oxazepam, Temazepam, Chlordiazepoxide, Lorazepam, Clonazepam, Alprazolam, Midazolam, Cocaine, Benzoylecgonine, Cocaethylene, Methadone, EDDP, Codeine - Free, Morphine - Free, Hydrocodone - Free, 6-Monoacetylmorphine - Free, Hydromorphone - Free, Oxycodone - Free, Oxymorphone - Free, Dihydrocodeine - Free, Phencyclidine, Dextromethorphan

Compound Name	Units	Reference Comment
Hydrocodone - Free	ng/mL	Hydrocodone (Vicodin, Lortab) is a schedule II opioid with narcotic analgesic, and antitussive properties.

8897OF Drugs of Abuse (7 Panel) (Qualitative), Oral Fluid (Saliva)

Summary of Changes: Reference Comment was changed.

Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80324, 80346, 80353, 80356, 80358, 80359, 80361, 80362):
Method (CPT Code) Amphetamine, Methamphetamine, MDA, MDMA, Diazepam, Nordiazepam, Oxazepam, Temazepam, Chlordiazepoxide, Lorazepam, Clonazepam, Alprazolam, Midazolam, Cocaine, Benzoylecgonine, Cocaethylene, Methadone, EDDP, Codeine - Free, Morphine - Free, Hydrocodone - Free, 6-Monoacetylmorphine - Free, Hydromorphone - Free, Oxycodone - Free, Oxymorphone - Free, Dihydrocodeine - Free, Phencyclidine, Dextromethorphan
GC/MS (80349): Delta-9 THC

Compound Name	Units	Reference Comment
Hydrocodone - Free	ng/mL	Hydrocodone (Vicodin, Lortab) is a schedule II opioid with narcotic analgesic, and antitussive properties.

1900SP Dyazide, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 24 month(s)

2069B Felbamate, Blood

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80339): Felbamate
Method (CPT Code)

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Felbamate	mcg/mL	Fifty-six adult patients receiving an average daily oral dose of 2300 mg had steady-state trough plasma concentrations averaging 33 mcg/mL (range, 18-52 mcg/mL). Twenty-six patients ages 10-69 years receiving an average daily dose of 2685 mg had serum concentrations averaging 69 mcg/mL (range, 16-165 mcg/mL). The ratio of whole blood concentration to plasma concentration is 1.0.

2069SP Felbamate, Serum/Plasma

Summary of Changes:	Specimen Requirements were changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Stability was changed. Reference Comment was changed.

Specimen Requirements:	1 mL Serum or Plasma
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	Serum: Collect sample in Red top tube Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube. Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria:	Polymer gel separation tube (SST or PST).
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Felbamate

Compound Name	Units	Reference Comment
Felbamate	mcg/mL	Fifty-six adult patients receiving an average daily oral dose of 2300 mg had steady-state trough plasma concentrations averaging 33 mcg/mL (range, 18-52 mcg/mL). Twenty-six patients ages 10-69 years receiving an average daily dose of 2685 mg had serum concentrations averaging 69 mcg/mL (range, 16-165 mcg/mL).

2100B Fluorocarbons (22, 113) Panel, Blood

Test Updates

Test Changes

Summary of Changes:	Test Name was changed. Specimen Requirements (Specimen Container) were changed. Specimen Requirements (Special Handling) were changed. Scope of Analysis was changed. Dichlorodifluoromethane and Trichlorofluoromethane were removed.
Specimen Requirements:	2 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	Ensure that container remains tightly sealed.
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	GC (84600): Chlorodifluoromethane, Trichlorotrifluoroethane

2100TI Fluorocarbons (22, 113) Panel, Tissue

Summary of Changes:	Test Name was changed. Scope of Analysis was changed. Dichlorodifluoromethane and Trichlorofluoromethane were removed.
Scope of Analysis: Method (CPT Code)	GC (84600): Chlorodifluoromethane, Trichlorotrifluoroethane

52155SP Furosemide Confirmation, Serum/Plasma (Forensic) (CSA)

Summary of Changes:	Stability was changed.
Stability:	Room Temperature: 14 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 24 month(s)

9545SP Furosemide Screen (Add-On), Serum/Plasma (Forensic) (CSA)

Summary of Changes:	Stability was changed.
Stability:	Room Temperature: 14 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 24 month(s)

2140SP Furosemide, Serum/Plasma

Summary of Changes:	Stability was changed.
Stability:	Room Temperature: 14 day(s) Refrigerated: 1 month(s) Frozen (-20 °C): 24 month(s)

52156SP Hydrochlorothiazide Confirmation, Serum/Plasma (Forensic) (CSA)

Test Updates

Test Changes

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 24 month(s)

9546SP Hydrochlorothiazide Screen (Add-On), Serum/Plasma (Forensic) (CSA)

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 24 month(s)

2330SP Hydrochlorothiazide, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 24 month(s)

2345SP Hydroflumethiazide, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 24 month(s)

2365U Hydroxyzine and Metabolite, Urine

Summary of Changes: Stability was changed.

Stability: Room Temperature: 1 month(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 6 month(s)

2397SP Indapamide, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 1 month(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 24 month(s)

2414B Inhalants Panel, Halocarbons, Blood

Summary of Changes: Scope of Analysis was changed.
Dichlorodifluoromethane and Trichlorofluoromethane were removed.

Test Updates

Test Changes

Scope of Analysis: GC (84600): Carbon Tetrachloride, Chloroform, Dichloromethane,
Method (CPT Code) Trichlorotrifluoroethane, 1,1,1-Trichloroethane, Tetrachloroethylene,
Trichloroethylene

2414TI Inhalants Panel, Halocarbons, Tissue

Summary of Changes: Scope of Analysis was changed.
Dichlorodifluoromethane and Trichlorofluoromethane were removed.

Scope of Analysis: GC (84600): Carbon Tetrachloride, Chloroform, Dichloromethane,
Method (CPT Code) Trichlorotrifluoroethane, 1,1,1-Trichloroethane, Tetrachloroethylene,
Trichloroethylene

54355B Lacosamide Confirmation (Drug Impaired Driving/DRE Toxicology), Blood (Forensic)

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Blood
Transport Temperature: Refrigerated
Specimen Container: Lavender top tube (EDTA)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: Received Room Temperature.
Stability: Room Temperature: 1 day(s)
Refrigerated: 7 day(s)
Frozen (-20 °C): 30 day(s)
Scope of Analysis: LC-MS/MS (80339): Lacosamide
Method (CPT Code)

Compound Name	Units	Reference Comment
Lacosamide	mcg/mL	Peak plasma concentrations are reached 1 to 2 hours after a single oral or intravenous dose with a half-life of 13 hours. Following a single 200 mg dose administered as a 30-minute infusion, a 60-minute infusion, or orally as a tablet to 24 male subjects, mean maximum plasma lacosamide concentrations were 5.95 +/- 1.49, 5.38 +/- 1.10 and 5.15 +/- 1.4 mcg/mL, respectively. Mean plasma concentrations following maintenance doses: 200 mg/day: 4.99 +/- 2.51 mcg/mL; 400 mg/day: 9.35 +/- 4.22 mcg/mL; 600 mg/day: 12.46 +/- 5.60 mcg/mL. The ratio of whole blood concentration to plasma concentration is 1.1

Test Updates

Test Changes

54355SP Lacosamide Confirmation (Drug Impaired Driving/DRE Toxicology), Serum/Plasma (Forensic)

Summary of Changes: Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 10 month(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (80339): Lacosamide

Compound Name	Units	Reference Comment
Lacosamide	mcg/mL	Peak plasma concentrations are reached 1 to 2 hours after a single oral or intravenous dose with a half-life of 13 hours. Following a single 200 mg dose administered as a 30-minute infusion, a 60-minute infusion, or orally as a tablet to 24 male subjects, mean maximum plasma lacosamide concentrations were 5.95 +/- 1.49, 5.38 +/- 1.10 and 5.15 +/- 1.4 mcg/mL, respectively. Mean plasma concentrations following maintenance doses: 200 mg/day: 4.99 +/- 2.51 mcg/mL; 400 mg/day: 9.35 +/- 4.22 mcg/mL; 600 mg/day: 12.46 +/- 5.60 mcg/mL. NMS Labs derived data: 5th - 95th Percentile Data: 1.8 - 13.0 mcg/mL Mean: 5.3 mcg/mL (N = 14900)

54355U Lacosamide Confirmation (Drug Impaired Driving/DRE Toxicology), Urine (Forensic)

Summary of Changes: Specimen Requirements were changed.
Reference Comment was changed.

Test Updates

Test Changes

Specimen Requirements:	2 mL Urine
Transport Temperature:	Refrigerated
Specimen Container:	Plastic container (preservative-free)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	None
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Lacosamide

Compound Name	Units	Reference Comment
Lacosamide	mcg/mL	Lacosamide is a functionalized amino acid specifically synthesized as an anticonvulsant drug. In addition to being approved for use as an adjunctive therapy treatment of partial-onset seizures it has been investigated as a treatment for diabetic neuropathic pain. Lacosamide can be administered either orally or intravenously. The recommended initial dose is 50 mg/twice a day, up to a maintenance dose of 200 to 400 mg/day. Single labeled oral or intravenous lacosamide doses in healthy subjects were eliminated in urine (95%) and feces (< 0.5%) over a 7 day interval. Urinary excretion products included parent drug (40% of the dose) and the pharmacologically inactive O-desmethyllacosamide.

52420B Lacosamide Confirmation, Blood (Forensic)

Summary of Changes:	Stability was changed. Reference Comment was changed.
Stability:	Room Temperature: 1 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Lacosamide

Compound Name	Units	Reference Comment
Lacosamide	mcg/mL	Peak plasma concentrations are reached 1 to 2 hours after a single oral or intravenous dose with a half-life of 13 hours. Following a single 200 mg dose administered as a 30-minute infusion, a 60-minute infusion, or orally as a tablet to 24 male subjects, mean maximum plasma lacosamide concentrations were 5.95 +/- 1.49, 5.38 +/- 1.10 and 5.15 +/- 1.4 mcg/mL, respectively. Mean plasma concentrations following maintenance doses:

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		200 mg/day: 4.99 +/- 2.51 mcg/mL; 400 mg/day: 9.35 +/- 4.22 mcg/mL; 600 mg/day: 12.46 +/- 5.60 mcg/mL. The ratio of whole blood concentration to plasma concentration is 1.1

52420SP Lacosamide Confirmation, Serum/Plasma (Forensic)

Summary of Changes: Specimen Requirements (Special Handling) were changed.
Stability was changed.
Reference Comment was changed.

Specimen Requirements: 1 mL Serum or Plasma
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: Serum: Collect sample in Red top tube
Plasma: Collect sample in Lavender top tube (EDTA) or Pink top tube.
Promptly centrifuge and separate Serum or Plasma into a plastic screw capped vial using approved guidelines.
Rejection Criteria: Polymer gel separation tube (SST or PST).
Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 10 month(s)
Scope of Analysis: Method (CPT Code) LC-MS/MS (80339): Lacosamide

Compound Name	Units	Reference Comment
Lacosamide	mcg/mL	Peak plasma concentrations are reached 1 to 2 hours after a single oral or intravenous dose with a half-life of 13 hours. Following a single 200 mg dose administered as a 30-minute infusion, a 60-minute infusion, or orally as a tablet to 24 male subjects, mean maximum plasma lacosamide concentrations were 5.95 +/- 1.49, 5.38 +/- 1.10 and 5.15 +/- 1.4 mcg/mL, respectively. Mean plasma concentrations following maintenance doses: 200 mg/day: 4.99 +/- 2.51 mcg/mL; 400 mg/day: 9.35 +/- 4.22 mcg/mL;

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		600 mg/day: 12.46 +/- 5.60 mcg/mL. NMS Labs derived data: 5th - 95th Percentile Data: 1.8 - 13.0 mcg/mL Mean: 5.3 mcg/mL (N = 14900)

52420U Lacosamide Confirmation, Urine (Forensic)

Summary of Changes: Specimen Requirements were changed.
Reference Comment was changed.

Specimen Requirements: 2 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): LC-MS/MS (80339): Lacosamide

Compound Name	Units	Reference Comment
Lacosamide	mcg/mL	Lacosamide is a functionalized amino acid specifically synthesized as an anticonvulsant drug. In addition to being approved for use as an adjunctive therapy treatment of partial-onset seizures it has been investigated as a treatment for diabetic neuropathic pain. Lacosamide can be administered either orally or intravenously. The recommended initial dose is 50 mg/twice a day, up to a maintenance dose of 200 to 400 mg/day. Single labeled oral or intravenous lacosamide doses in healthy subjects were eliminated in urine (95%) and feces (< 0.5%) over a 7 day interval. Urinary excretion products included parent drug (40% of the dose) and the pharmacologically inactive O-desmethyllacosamide.

2527B Lacosamide, Blood

Summary of Changes: Specimen Requirements (Specimen Container) were changed.
Stability was changed.
Reference Comment was changed.

Test Updates

Test Changes

Specimen Requirements:	1 mL Blood
Transport Temperature:	Refrigerated
Specimen Container:	Lavender top tube (EDTA)
Light Protection:	Not Required
Special Handling:	None
Rejection Criteria:	Received Room Temperature.
Stability:	Room Temperature: 1 day(s) Refrigerated: 7 day(s) Frozen (-20 °C): 30 day(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Lacosamide

Compound Name	Units	Reference Comment
Lacosamide	mcg/mL	Peak plasma concentrations are reached 1 to 2 hours after a single oral or intravenous dose with a half-life of 13 hours. Following a single 200 mg dose administered as a 30-minute infusion, a 60-minute infusion, or orally as a tablet to 24 male subjects, mean maximum plasma lacosamide concentrations were 5.95 +/- 1.49, 5.38 +/- 1.10 and 5.15 +/- 1.4 mcg/mL, respectively. Mean plasma concentrations following maintenance doses: 200 mg/day: 4.99 +/- 2.51 mcg/mL; 400 mg/day: 9.35 +/- 4.22 mcg/mL; 600 mg/day: 12.46 +/- 5.60 mcg/mL. The ratio of whole blood concentration to plasma concentration is 1.1.

10020SP Lacosamide, Serum/Plasma (CSA)

Summary of Changes:	Stability was changed. Reference Comment was changed.
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 10 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Lacosamide

Test Updates

Test Changes

Compound Name	Units	Reference Comment
Lacosamide	mcg/mL	Peak plasma concentrations are reached 1 to 2 hours after a single oral or intravenous dose with a half-life of 13 hours. Following a single 200 mg dose administered as a 30-minute infusion, a 60-minute infusion, or orally as a tablet to 24 male subjects, mean maximum plasma lacosamide concentrations were 5.95 +/- 1.49, 5.38 +/- 1.10 and 5.15 +/- 1.4 mcg/mL, respectively. Mean plasma concentrations following maintenance doses: 200 mg/day: 4.99 +/- 2.51 mcg/mL; 400 mg/day: 9.35 +/- 4.22 mcg/mL; 600 mg/day: 12.46 +/- 5.60 mcg/mL. NMS Labs derived data: 5th - 95th Percentile Data: 1.8 - 13.0 mcg/mL Mean: 5.3 mcg/mL (N = 14900)

2527SP Lacosamide, Serum/Plasma

Summary of Changes:	Stability was changed. Reference Comment was changed.
Stability:	Room Temperature: 30 day(s) Refrigerated: 30 day(s) Frozen (-20 °C): 10 month(s)
Scope of Analysis: Method (CPT Code)	LC-MS/MS (80339): Lacosamide

Compound Name	Units	Reference Comment
Lacosamide	mcg/mL	Peak plasma concentrations are reached 1 to 2 hours after a single oral or intravenous dose with a half-life of 13 hours. Following a single 200 mg dose administered as a 30-minute infusion, a 60-minute infusion, or orally as a tablet to 24 male subjects, mean maximum plasma lacosamide concentrations were 5.95 +/- 1.49, 5.38 +/- 1.10 and 5.15 +/- 1.4 mcg/mL, respectively. Mean plasma concentrations following maintenance doses: 200 mg/day: 4.99 +/- 2.51 mcg/mL; 400 mg/day: 9.35 +/- 4.22 mcg/mL;

Test Updates

Test Changes

Compound Name	Units	Reference Comment
		600 mg/day: 12.46 +/- 5.60 mcg/mL. NMS Labs derived data: 5th - 95th Percentile Data: 1.8 - 13.0 mcg/mL Mean: 5.3 mcg/mL (N = 14900)

2527U Lacosamide, Urine

Summary of Changes: Specimen Requirements were changed.
Reference Comment was changed.

Specimen Requirements: 2 mL Urine
Transport Temperature: Refrigerated
Specimen Container: Plastic container (preservative-free)
Light Protection: Not Required
Special Handling: None
Rejection Criteria: None
Scope of Analysis: Method (CPT Code): LC-MS/MS (80339): Lacosamide

Compound Name	Units	Reference Comment
Lacosamide	mcg/mL	Lacosamide is a functionalized amino acid specifically synthesized as an anticonvulsant drug. In addition to being approved for use as an adjunctive therapy treatment of partial-onset seizures it has been investigated as a treatment for diabetic neuropathic pain. Lacosamide can be administered either orally or intravenously. The recommended initial dose is 50 mg/twice a day, up to a maintenance dose of 200 to 400 mg/day. Single labeled oral or intravenous lacosamide doses in healthy subjects were eliminated in urine (95%) and feces (< 0.5%) over a 7 day interval. Urinary excretion products included parent drug (40% of the dose) and the pharmacologically inactive O-desmethyllacosamide.

3042SP Metolazone, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 7 day(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 24 month(s)

Test Updates

Test Changes

8895OF Opiates (Qualitative), Oral Fluid (Saliva)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80356, 80361, 80365): Codeine - Free, Morphine - Free, Hydrocodone - Free, 6-Monoacetylmorphine - Free, Hydromorphone - Free, Oxycodone - Free, Oxymorphone - Free, Dihydrocodeine - Free

Compound Name	Units	Reference Comment
Hydrocodone - Free	ng/mL	Hydrocodone (Vicodin, Lortab) is a schedule II opioid with narcotic analgesic, and antitussive properties.

5852OF Opiates Confirmation (Qualitative), Oral Fluid (Saliva) (Forensic)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80356, 80361, 80365): Codeine - Free, Morphine - Free, Hydrocodone - Free, 6-Monoacetylmorphine - Free, Hydromorphone - Free, Oxycodone - Free, Oxymorphone - Free, Dihydrocodeine - Free

Compound Name	Units	Reference Comment
Hydrocodone - Free	ng/mL	Hydrocodone (Vicodin, Lortab) is a schedule II opioid with narcotic analgesic, and antitussive properties.

8889OF ProofPOSITIVE® Drug Impaired Driving/DRE Toxicology Panel (Qualitative), Oral Fluid (Saliva) (CSA)

Summary of Changes: Reference Comment was changed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80324, 80346, 80353, 80356, 80358, 80359, 80361, 80362): Amphetamine, Methamphetamine, MDA, MDMA, Diazepam, Nordiazepam, Oxazepam, Temazepam, Chlordiazepoxide, Lorazepam, Clonazepam, Alprazolam, Midazolam, Codeine - Free, Morphine - Free, Hydrocodone - Free, 6-Monoacetylmorphine - Free, Hydromorphone - Free, Oxycodone - Free, Oxymorphone - Free, Dihydrocodeine - Free, Cocaine, Benzoylecgonine, Cocaethylene, Methadone, EDDP, Phencyclidine, Dextromethorphan

Compound Name	Units	Reference Comment
Hydrocodone - Free	ng/mL	Hydrocodone (Vicodin, Lortab) is a schedule II opioid with narcotic analgesic, and antitussive properties.

4125B Rufinamide, Blood

Summary of Changes: Stability was changed.
Reference Comment was changed.
Units were changed.

Stability: Room Temperature: 30 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 6 month(s)

Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80339): Rufinamide
Method (CPT Code)

Compound Name	Units	Reference Comment
Rufinamide	mcg/mL	Maintenance therapy with 45 mg/kg (approximately 1600 mg) daily rufinamide resulted in plasma concentrations ranging from 5.0 - 48 mcg/mL (n = 74). Trough plasma concentrations in groups of 129-133 patients maintained on twice-daily 400 or 800 mg doses for 3 months averaged 2.6 or 4.7 mcg/mL, respectively. The blood to plasma ratio of rufinamide is approximately 1.0

4125SP Rufinamide, Serum/Plasma

Summary of Changes: Stability was changed.
Reference Comment was changed.
Units were changed.

Stability: Room Temperature: 14 day(s)
Refrigerated: 30 day(s)
Frozen (-20 °C): 24 month(s)

Scope of Analysis: LC-MS/MS (80339): Rufinamide
Method (CPT Code)

Compound Name	Units	Reference Comment
Rufinamide	mcg/mL	Maintenance therapy with 45 mg/kg (approximately 1600 mg) daily rufinamide resulted in plasma concentrations ranging from 5.0 - 48 mcg/mL (n = 74). Trough plasma concentrations in groups of 129-133 patients maintained on twice-daily 400 or 800 mg doses for 3 months averaged 2.6 or 4.7 mcg/mL, respectively.

4525SP Torsemide, Serum/Plasma

Summary of Changes: Stability was changed.

Stability: Room Temperature: 1 month(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 24 month(s)

4540SP Triamterene, Serum/Plasma

Summary of Changes: Stability was changed.

Test Updates

Test Changes

Stability: Room Temperature: 1 month(s)
Refrigerated: 1 month(s)
Frozen (-20 °C): 24 month(s)

4844N Zinc, Nails

Summary of Changes: Reference Comment was changed.
Methods/CPT Codes were changed [ICP/OES (84630)]

Scope of Analysis: ICP/OES (84630): Zinc
Method (CPT Code)

Compound Name	Units	Reference Comment
Zinc	mcg/g	Normal: Generally averages approximately 200 mcg/g. Not for clinical diagnostic purposes.

NMS LABS
3701 Welsh Road
Willow Grove, PA 19090
www.NMSLabs.com

Effective Date:

Monday, May 04, 2015

Test Updates

Discontinued Tests

Test Code	Test Name	Alternative Test
3372B	PCBs, PBBs and Organochlorine Pesticides, Blood	3243B - Organochlorine Pesticides, Blood 3365B - PBBs Panel (Hexabrominated Biphenyls), Blood 3370B - PCBs Panel, Blood